Adjuvant immunotherapy for melanoma Review

  


Authors: Thomas, D.; Bello, D. M.
Review Title: Adjuvant immunotherapy for melanoma
Abstract: Surgical resection is the treatment for early cutaneous melanoma and is often curative. Some patients, however, will subsequently relapse. High-risk features in the primary tumor and regional lymph node metastasis highlight patient subsets that are at increased risk for recurrent disease. Immunotherapy in the form of checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have been shown to improve recurrence-free survival for node-positive melanoma in the adjuvant setting and will be the focus of this review. © 2020 Wiley Periodicals LLC
Keywords: adjuvant therapy; melanoma; immunotherapy; targeted therapy; stage iii
Journal Title: Journal of Surgical Oncology
Volume: 123
Issue: 3
ISSN: 0022-4790
Publisher: Wiley Blackwell  
Date Published: 2021-03-01
Start Page: 789
End Page: 797
Language: English
DOI: 10.1002/jso.26329
PROVIDER: scopus
PUBMED: 33595889
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100956117&doi=10.1002%2fjso.26329&partnerID=40&md5=5ebde7dc9b9ba4e15c1bf3747fa6fec4
Notes: Review -- Export Date: 1 March 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Danielle Marie Bello
    39 Bello
  2. Daniel Charles Thomas
    1 Thomas
Related MSK Work